| |
|
|
|
|
|
|
|||
|
Blood, 1 December 2008, Vol. 112, No. 12, pp. 4665-4674. Prepublished online as a Blood First Edition Paper on September 2, 2008; DOI 10.1182/blood-2008-02-139139.
Submitted February 14, 2008
Department of Clinical and Experimental Medicine, Hematology and Clinical Immunology Branch, Padua University School of Medicine, Padua, Italy * Corresponding author; email: g.semenzato{at}unipd.it.
Lyn, a tyrosine kinase belonging to the Src family, plays a key role as a switch molecule that couples the B cell receptor to downstream signalling. In B-CLL cells, Lyn is over-expressed, anomalously present in the cytosol and displays a high constitutive activity, as compared to normal B lymphocytes. The aim of this work was to gain insights into the molecular mechanisms underlying these aberrant properties of Lyn, which have already been demonstrated to be related to defective apoptosis in B-CLL cells. Herein, Lyn is described to be in an active conformation as integral component of an aberrant cytosolic 600 kDa multiprotein complex in B-CLL cells, associated with several proteins, such as Hsp90 through its catalytic domain, and HS1 and SHP-1L through its SH3 domain. In particular, Hsp90 appears tightly bound to cytosolic Lyn (CL), thus stabilizing the aberrant complex and converting individual transient interactions into stable ones. We also demonstrate that treatment of B-CLL cells with geldanamycin, an Hsp90 inhibitor already reported to induce cell death, is capable of dissociating the CL complex in the early phases of apoptosis and thus inactivating CL itself. These data identify the CL complex as a potential target for therapy in B-CLL.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Copyright © 2008 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||